BCPC241220P170000
- 0.00
- 0.000.00%
Balchem Newsroom
Balchem Is Maintained at Buy by HC Wainwright & Co.
H.C. Wainwright Maintains Balchem(BCPC.US) With Buy Rating, Raises Target Price to $190
Balchem's Strong Growth Potential and Strategic Advancements Drive Buy Rating
Balchem Price Target Raised to $185.00/Share From $170.00 by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Balchem, Raises Price Target to $185
Balchem Analyst Ratings
Buy Rating Affirmed for Balchem With Raised Price Target Amidst Strong Profitability and Growth Prospects
H.C. Wainwright Maintains Balchem(BCPC.US) With Buy Rating, Raises Target Price to $185
HC Wainwright & Co. : The Balchem (BCPC.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $167.00 to $170.00.
Buy Rating Affirmed for Balchem With Strong Q1 Performance and Positive Growth Outlook
Balchem Analyst Ratings
HC Wainwright & Co. Maintains Buy on Balchem, Raises Price Target to $170
HC Wainwright & Co. Maintains Buy on Balchem, Lowers Price Target to $135
Balchem Analyst Ratings
HC Wainwright & Co. Maintains Buy on Balchem, Raises Price Target to $165
Balchem Analyst Ratings
HC Wainwright Adjusts Price Target on Balchem to $150 From $140, Keeps Buy Rating
Analysts Offer Insights on Healthcare Companies: Agenus (AGEN) and Balchem (BCPC)
HC Wainwright & Co. Maintains Buy on Balchem, Raises Price Target to $150
HC Wainwright Adjusts Price Target on Balchem to $140 From $152, Keeps Buy Rating